The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.
The conversation is about the release of a new phase3clinical trial for a year and questioning if the results of the 6-month clinicaltrials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase3clinicaltrials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase3clinicaltrials of Pyrilutamide, which is likely to be approved by the FDA soon.
12 companies having drugs or therapies in clinicaltrials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.